share_log

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 Third Quarter Results

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 Third Quarter Results

沃尔格林-联合博姿 | 8-K:沃尔格林靴子联盟公布2024财年第三季度业绩
美股SEC公告 ·  2024/06/27 04:08

Moomoo AI 已提取核心信息

Walgreens Boots Alliance reported Q3 FY2024 sales of $36.4 billion, up 2.6% YoY, while adjusted EPS declined 36.6% to $0.63, impacted by lower sale-leaseback gains and challenging U.S. retail environment. The company lowered its FY2024 adjusted EPS guidance to $2.80-$2.95 due to persistent pharmacy margin pressures and weak consumer spending.The company announced strategic initiatives including optimization of U.S. store footprint, launching retail pharmacy action plan, and simplifying healthcare portfolio. Q3 operating income was $111 million compared to a loss of $477 million last year. U.S. Retail Pharmacy segment saw comparable sales increase of 3.5%, while International segment grew 2.8%.Free cash flow improved to $334 million, up $778 million YoY, driven by working capital optimization and reduced capital expenditures. The U.S. Healthcare segment achieved positive adjusted EBITDA of $23 million, marking second consecutive quarter of profitability improvement.
Walgreens Boots Alliance reported Q3 FY2024 sales of $36.4 billion, up 2.6% YoY, while adjusted EPS declined 36.6% to $0.63, impacted by lower sale-leaseback gains and challenging U.S. retail environment. The company lowered its FY2024 adjusted EPS guidance to $2.80-$2.95 due to persistent pharmacy margin pressures and weak consumer spending.The company announced strategic initiatives including optimization of U.S. store footprint, launching retail pharmacy action plan, and simplifying healthcare portfolio. Q3 operating income was $111 million compared to a loss of $477 million last year. U.S. Retail Pharmacy segment saw comparable sales increase of 3.5%, while International segment grew 2.8%.Free cash flow improved to $334 million, up $778 million YoY, driven by working capital optimization and reduced capital expenditures. The U.S. Healthcare segment achieved positive adjusted EBITDA of $23 million, marking second consecutive quarter of profitability improvement.
2024年6月27日,Walgreens Boots Alliance,Inc。(WBA)公布了截至2024年5月31日的财政季度财务报告。公司宣布调整后每股收益(EPS)按固定汇率计算同比下降36.6%,原因是低销售租回收益,美国零售环境严峻和近期药房行业趋势。尽管面临这些挑战,第三季度销售同比增长2.6%至364亿美元。 WBA还将其2024财年调整后EPS指导下调至2.80至2.95美元,反映了行业持续面临的挑战和美国消费者环境低于预期的状况。此外,公司正在最终确定一项重要的多年足迹优化计划,以关闭某些业绩不佳的美国商店,并推出美国零售药房行动计划以投资和改善客户和患者体验。公司CEO Tim Wentworth对领导业务转型的团队和策略表达了信恳智能。该财务报告附带了一次电话会议和网络直播,讨论了结果和相关事宜。
2024年6月27日,Walgreens Boots Alliance,Inc。(WBA)公布了截至2024年5月31日的财政季度财务报告。公司宣布调整后每股收益(EPS)按固定汇率计算同比下降36.6%,原因是低销售租回收益,美国零售环境严峻和近期药房行业趋势。尽管面临这些挑战,第三季度销售同比增长2.6%至364亿美元。 WBA还将其2024财年调整后EPS指导下调至2.80至2.95美元,反映了行业持续面临的挑战和美国消费者环境低于预期的状况。此外,公司正在最终确定一项重要的多年足迹优化计划,以关闭某些业绩不佳的美国商店,并推出美国零售药房行动计划以投资和改善客户和患者体验。公司CEO Tim Wentworth对领导业务转型的团队和策略表达了信恳智能。该财务报告附带了一次电话会议和网络直播,讨论了结果和相关事宜。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息